Dexamethasone | |||
---|---|---|---|
Total | Discretionary | Mandatory | |
Variable | (n=163) | (n=89) | (n=74) |
Median age (range), years | 68 (38–86) | 67 (38–81) | 69 (48–86) |
Sex | |||
Male | 98 | 57 | 41 |
Female | 65 | 32 | 33 |
Histology | |||
Adenocarcinoma | 162 | 88 | 74 |
Large | 1 | 1 | 0 |
Stage | |||
IIIA | 8 | 4 | 4 |
IIIB | 18 | 14 | 4 |
IV | 91 | 47 | 44 |
Recurrence | 46 | 24 | 22 |
Line of chemotherapy | |||
First | 60 | 25 | 35 |
Second | 50 | 32 | 18 |
≥Third | 53 | 32 | 21 |
Regimens | |||
CBDCA+PEM | 58 | 34 | 24 |
CBDCA+PEM+Bev | 21 | 9 | 21 |
PEM+Bev | 13 | 0 | 13 |
PEM | 71 | 46 | 25 |
Bev, bevacizumab; CBDCA, carboplatin; PEM, pemetrexed.